Literature DB >> 28843767

Carfilzomib versus bortezomib: no longer an ENDEAVOR.

Niels Wcj van de Donk1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28843767     DOI： 10.1016/S1470-2045(17)30613-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease.

Authors:  Juraj Adamik; G David Roodman; Deborah L Galson
Journal:  JBMR Plus       Date:  2019-03-15

2.  Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.

Authors:  Robert R Redfield; Stanley C Jordan; Stephan Busque; Flavio Vincenti; E Steve Woodle; Niraj Desai; Elaine F Reed; Simon Tremblay; Andrea A Zachary; Ashley A Vo; Richard Formica; Thomas Schindler; Ha Tran; Caroline Looney; Candice Jamois; Cherie Green; Alyssa Morimoto; Richa Rajwanshi; Aaron Schroeder; Matthew D Cascino; Paul Brunetta; Dominic Borie
Journal:  Am J Transplant       Date:  2019-07-23       Impact factor: 8.086

Review 3.  Emerging agents and regimens for multiple myeloma.

Authors:  Yang Yang; Yi Li; Huiyao Gu; Mengmeng Dong; Zhen Cai
Journal:  J Hematol Oncol       Date:  2020-11-09       Impact factor: 17.388

Review 4.  T-Type Calcium Channels: A Mixed Blessing.

Authors:  Dario Melgari; Anthony Frosio; Serena Calamaio; Gaia A Marzi; Carlo Pappone; Ilaria Rivolta
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.